Novartis: Alcon Acquires Tear Film Innovations
December 19 2018 - 2:03AM
Dow Jones News
By Alberto Delclaux
Novartis AG (NOVN.EB) said Wednesday that its eye-care division
Alcon has bought Tear Film Innovations, a company that manufactures
a therapeutic device used to treat a leading cause of a condition
know as dry eye.
Tear Film's iLux device, for the treatment of meibomian gland
dysfunction, received 510(k) clearance from the U.S. Food and Drug
Administration in December 2017 and was officially launched in May
2018, Novartis said.
"With the acquisition of Tear Film, we're excited to bring this
latest innovation to treat the millions of people around the world
who suffer from dry eye," said Andy Pawson, president of Alcon's
global vision care franchise.
Write to Alberto Delclaux at alberto.delclaux@dowjones.com
(END) Dow Jones Newswires
December 19, 2018 01:48 ET (06:48 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novartis (NYSE:NVS)
Historical Stock Chart
From Apr 2023 to Apr 2024
